Semaglutide calculators

Semaglutide is a synthetic peptide that mimics glucagon-like peptide-1, a hormone the gut releases after eating. It became one of the most widely used peptides in the world after pharmaceutical formulations — sold under brand names like Ozempic and Wegovy — gained regulatory approval for blood-sugar management and weight management.

In a research and personal-logging context, semaglutide is almost always supplied as a lyophilized white powder inside a small glass vial, rated in milligrams of active peptide. The vial has to be reconstituted with bacteriostatic water before any volume can be drawn into a syringe. Common vial sizes seen in the research market range from 2 mg up to 10 mg or larger.

Because semaglutide is long-acting — its half-life is roughly a week — it is typically logged on a weekly cadence. That single property shapes everything about how the peptide is dosed, how often a vial is opened, and how vial duration is calculated for refill planning.

GLP-1 agonists bind to receptors in the pancreas and the brain. Activating the pancreatic receptor influences insulin and glucagon release in response to glucose; activating the central receptor influences appetite and gastric emptying. Semaglutide is engineered to resist enzymatic breakdown, which is what gives it its long half-life relative to native GLP-1.

Researchers and individuals tracking semaglutide are usually looking at weekly weight, hunger ratings, blood sugar readings, and side-effect notes alongside the dose log itself. Pairing those metrics with the dose history is how patterns become visible — for example, whether a dose change correlated with a change in hunger ratings the following week.

The ~7-day half-life mathematically dictates how Semaglutide accumulates in the body to reach a steady-state concentration. After the first weekly dose, approximately 50% of the peptide remains after seven days, at which point the second dose is administered. This new dose adds to the remaining concentration from the first. This stacking process continues with each subsequent weekly administration, with the total amount of the peptide present in the body incrementally increasing. After approximately four to five half-lives, or four to five weeks, the amount being eliminated over the week becomes roughly equal to the amount being added, establishing a concentration plateau known as steady state. This dynamic explains why logged observations during the first month may differ from those documented once this plateau is reached.

Weekly dosing is the default cadence for semaglutide because of its long half-life. Each injection is a small subcutaneous draw, almost always measured on a U-100 insulin syringe rather than a tuberculin syringe, because the volumes involved are very small.

Many semaglutide protocols start with a low weekly dose and escalate gradually over several weeks or months to reduce gastrointestinal side effects. Tracking that escalation accurately is one of the main reasons people move away from notes apps and toward a structured dose log: the cumulative pattern over months is what matters, and a pattern is hard to read from scattered text notes.

Skipped or delayed doses are recorded as deliberately as taken doses in most well-run logs, because gaps in the schedule meaningfully change the next week's planning. A vial-aware tracker also flags when the current vial is approaching empty so the next vial can be ordered in time, given semaglutide's typical four-to-six-week shipping windows.

When individuals plan to document a titration schedule observed in research studies, the core logging task becomes tracking the dose changes. A typical study protocol might involve starting at a low dose and stepping up that dose every four weeks. From a data-logging perspective, the calendar dates of these transitions are the most pivotal entries. Without a clear record of when the dose was increased from 0.25 mg to 0.5 mg, for example, it becomes impossible to later parse subjective or objective data and accurately attribute it to a specific dosage period. Therefore, a robust log must cleanly delineate each dosing chapter defined by the titration points.